Effect of Graded Heart Rate Reduction with Ivabradine on Myocardial Oxygen Consumption and Diastolic Time in Exercising Dogs

  1. Patrice Colin,
  2. Bijan Ghaleh,
  3. Xavier Monnet,
  4. Luc Hittinger and
  5. Alain Berdeaux
  1. Laboratoire de Pharmacologie, Institut National de la Santé et de la Recherche Médicale E 00.01, Faculté de Médecine Paris-Sud, Le Kremlin-Bicêtre, France (P.C., B.G., X.M., A.B.); Laboratoire de Pharmacologie, Faculté de Médecine Paris XII, Créteil, France (B.G., L.H., A.B.); and Fédération de Cardiologie, Hôpital Henri Mondor, Créteil, France (L.H.)
  1. Address correspondence to:
    Prof. Alain Berdeaux, Laboratoire de Pharmacologie, INSERM E 00.01, Faculté de Médecine Paris-Sud, 63, rue Gabriel Péri, 94270 Le Kremlin-Bicêtre, France. E-mail: alain.berdeaux{at}kb.u-psud.fr

Abstract

Lowering heart rate reduces myocardial oxygen consumption (MVO2) and produces potent anti-ischemic effects. The development of selective heart rate-reducing agents represents an alternative approach to the use of β-blockers. Therefore, our goal was to establish the dose-response curve of the effects of ivabradine (If channel inhibitor) on MVO2 and diastolic time. Seven conscious and chronically instrumented dogs were investigated during exercise at spontaneous and paced heart rate (250 beats/min) after administration of increasing doses of ivabradine (0.25, 0.5, and 1 mg/kg i.v.). During exercise, ivabradine dose dependently and significantly reduced the exercise-induced tachycardia (-17, -21, and -32% at 0.25, 0.5, and 1 mg/kg, respectively, versus saline) without altering myocardial contractility nor mean ejection wall stress. A linear relationship between heart rate (HR) and MVO2 was demonstrated (MVO2 = 0.044 × HR - 1.4; r = 0.987). These effects of ivabradine on MVO2 were abolished by atrial pacing. Similarly, ivabradine dose dependently increased diastolic time without altering the inverse and non linear relationship between diastolic time and heart rate observed with saline. In conclusion, selective heart rate reduction with ivabradine dose dependently increases diastolic time and reduces MVO2 with a linear relationship between heart rate and MVO2. The lack of “on-off” pharmacological profile will predict the possibility of using a wide range of dose regimen.

Footnotes

  • DOI: 10.1124/jpet.103.059717.

  • This study was supported by a grant from the Fondation de France (2001-005170). P.C. was a recipient of the Société Française de Pharmacologie.

  • ABBREVIATIONS: MVO2, myocardial oxygen consumption; LV dP/dt, first derivative of left ventricular pressure over time; HR, heart rate; DT, diastolic time.

    • Received September 9, 2003.
    • Accepted October 6, 2003.
« Previous | Next Article »Table of Contents